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Abstract 
Background and purpose 
The lack of selective sodium-calcium exchanger (NCX) inhibitors has hampered the exploration of 
physiological and pathophysiological roles of cardiac NCX 1.1. We aimed to discover more potent and 
selective drug like NCX 1.1. inhibitor. 
Experimental approach 
A flavan series-based pharmacophore model was constructed. Virtual screening helped us identify a 
novel scaffold for NCX inhibition. A distinctively different NCX 1.1 inhibitor, ORM-11372, was 
discovered after lead optimization. Its potency against human and rat NCX 1.1 and selectivity against 
other ion channels was assessed. The cardiovascular effects of ORM-11372 were studied in normal 
and infarcted rats, and rabbits. Human cardiac safety was studied ex-vivo using human ventricular 
trabeculae. 
Key results 
ORM-11372 inhibited human NCX 1.1 reverse and forward currents; IC50 values were 5 and 6 nM, 
respectively. ORM-11372 inhibited human cardiac sodium 1.5 (INa) and hERG KV11.1 currents (IhERG) in 
a concentration-dependent manner; IC50 values were 23.2 and 10.0 µM. ORM-11372 caused no changes 
in action potential duration; short term variability and triangulation were observed for 
concentrations of upto 10 µM. 
ORM-11372 induced positive inotropic effects in 18 ± 6% and 35 ± 8% anesthetized rats with myocardial 
infarctions and rabbits, respectively; no other haemodynamic effects were observed, except 
improved relaxation at the lowest dose. 
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Conclusion and implications 
ORM-11372, a unique, novel, and potent inhibitor of human and rat NCX 1.1, is a positive inotropic 
compound. NCX inhibition can induce clinically relevant improvements in left ventricular contractions 
without affecting relaxation, heart rate, or blood pressure, without pro-arrhythmic risk. 
Keywords: 
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Abbreviations 
Amax Maximum amplitude of action potential 
AP Action potential 
APD90 Action potential duration 90% 
ARRIVE Animal research: reporting in vivo experiments 
Cav Voltage dependent Ca
2+ channel 
CHO-K1 Chinese Hamster Ovary cells, subtype 
cLogP Calculated logarithm of partition coefficient 
cLogS Calculated logarithm of solubility 
CM Cardiomyocyte 
ECC Exitation-contraction coupling 
FCCP Carbonyl cyanide 4-(trifluoromethoxyl) 
Fluo-4 Ca2+ dye 
[3H]NE Tritium labelled norepinephrine 
HAM F-12 Ham’s Nutrient Mixture F12 
HIPAA Health Insurance Portability and Accountability Act 
HR Heart rate 
hSCN5 Human sodium voltage-gated channel subunit 5 
ICAL L-type Ca
2+ channel current 
IhERG Human ether-á-go-go-related gene-encoded voltage dependent potassium channel 
current 
IMR-32 Human neuroblastoma cell line 
INa Human cardiac sodium 1.5 current 
INCX Na
+/Ca2+ exchanger current 
hiPSC Human induced pluripotent stem cell 
IRB Institutional Review Board 
KATP ATP dependent potassium channel 
KCNH2 Potassium Voltage-Gated Channel, Subfamily H (Eag-related), Member 2 
Kv Voltage dependent potassium channel 
Kv11.1 Alpha subunit of a potassium ion channel 
LQT Long QT time 
LVP Left ventricular pressure 
LV+dP/dtmax Left ventricular inotropic effect 
LV-dP/dtmin Left ventricular relaxation 
m-                  Meta-position 
MEM Minimum Essential Medium 
MI Myocardial infarction  
mOsm Milliosmoles 
MRSA Methicillin-resistant Staphylococcocus aureus 
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Na2ATP Adenosine 5′-triphosphate disodium salt hydrate 
NaBH4 Sodium borohydride 
Nav1.5 Voltage-gated sodium channel, alpha subunit 5 
NC3Rs National centre for replacement, refinement, reduction of animals in research 
NCX Sodium-calcium exchanger 
NCXIF Intrinsic factor inhibiting NCX 
NIH National Institute of Health 
PMCA Plasma membrane Ca2+ ATPase 
p- Para-position  
RMP Resting Membrane Potential 
rpm rounds per minute 
SAR Structure Activity Relationship 
SCN5A Voltage-gated sodium channel alpha subunit 5 (i.e.Nav1.5) 
Sf9 Insect cell Spodoptera frugiperda 
SKCa Small conductance calcium dependent potassium channel 
SLC8 Solute carrier transporter gene family 
SP Systemic blood pressure 
STV Short term variability analysis of action potential duration 
TEACl Tetraethylammonium Chloride 
TNM-FH  Insect cell culture medium 
XIP Exchanger inhibiting peptide 
Summary: 
What is already known 
 NCX plays a pathological role in heart failure, cardiac ischemia, and arrhythmia. 
 Known NCX modulators are unselective small molecules or peptides. 
What this study adds 
 The newly-discovered NCX inhibitor was the most potent and selective. 
 Positive inotropic effect in in vivo rabbits and no pro-arrhytmic risk in human cardiac 
tissue. 
Clinical significance 
 Positive inotropic effect without effects on other haemodynamic parameters. 
Introduction 
Sodium-calcium exchanger (NCX) has dynamic role in exitation-contraction coupling (ECC) in 
cardiomyocytes. The driving force of NCX depends on sodium and calcium concentrations across cell 
membrane cell as well as membrane potential. NCX operates dominantly in the forward mode (Ca2+ 
extrusion and inducing depolarizating current) during systole in all species. Therefore, selective NCX 
inhibitors have only minor effect on peak [Ca2+]i in mice and dogs (Kohajda et al., 2016; Kormos et 
al., 2014; Oravecz et al., 2018). In addition, both mechanical relaxation and [Ca2+]i decay remained 
unchanged (Kormos et al., 2014). Selective NCX inhibitors either slightly shorten action potential 
duration or have no effect in normal oxygen and ionic conditions. Overall it seems that selective NCX 
inhibition has minimal effect on intracellular Ca2+ or APD under normal conditions.  
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In heart failure, the intracellular Ca2+ concentration balance is changed, and the role of NCX becomes 
even more important (Bers et al., 2006). In addition, NCX and intracellular Ca2+ regulate each other 
and affect cardiac remodeling, as described in a very recent study (Primessnig et al., 2019). ORM-
11035, a selective NCX inhibitor, attenuated cardiac hypertrophic remodeling and prevented cardiac 
dysfunction in rats exhibiting heart failure. NCX also reportedly controls the heart rate through its 
effects on the sinus and atrioventricular nodes (Kaese et al., 2017). In sinus node, funny current (If) 
and NCX current (INCX) together establish a strong depolarization capacity providing important safety 
factor for stable pacemaking (Kohajda et al., 2019). NCX also plays a role in blood pressure control 
in normotensive and hypertensive individuals (Zhang, 2013). 
The SLC8 gene family encodes several Na+/Ca2+ exchanger subtypes. SLC8A1 gene overexpression and 
NCX1.1 protein upregulation is linked to many pathological conditions that lead to reduced 
contractility and arrhythmias (Khananshvili, 2013). NCX is organized into ten transmembrane 
segments and is localized in the sarcolemmal membrane (Jost et al., 2013; Shattock et al., 2015). 
Two Ca2+ binding domains are known currently. Their activation is regulated by Ca2+ binding at these 
sites, whereas Na+ binding leads to NCX inactivation (Hilgemann et al., 1992). 
Several potent NCX inhibitors have been reported (Table S1). In 1996, KB-R7943 was the first NCX 
inhibitor to be discovered. SN-6 (Iwamoto et al., 2004) and SEA0400 (Matsuda et al., 2001) were 
reported to be more selective NCX inhibitors than KB-R7943. YM-244769 (Iwamoto et al., 2006), which 
was discovered in 2006, was reported to be a novel NCX inhibitor with higher selectivity. ORM-10103 
(Koskelainen et al., 2003) was discovered in 2013, followed by ORM-10962 (Otsomaa et al., 2004) and 
GYKB-6635 (Geramipour et al., 2016) in 2016; they were highly selective NCX inhibitors (Jost et al., 
2013; Kohajda et al., 2016). Despite their higher selectivity, their poor solubility as positive inotropic 
tool compounds in in vivo experiments (solubility of SEA0400 is less than 10 µg/ml into pH 7.4 
phosphate buffer i.e. solubility class insoluble) prevented their use. ORM-10962 is an exception from 
previously reported selective NCX inhibitors, as it exhibits reasonable solubility in in vivo studies. 
Here, we describe the discovery of a new type of positive inotropic compound, ORM-11372, exhibiting 
high NCX1.1 selectivity and pharmacological profiling in vitro, in vivo, and ex-vivo in human 
ventricular trabeculae. ORM-11372 was developed for acute short-term use with fast clearance. 
Materials and Methods 
Discovery of a novel chemical series 
A novel and unique chemical series was discovered using ligand-based pharmacophores for virtual 
screening with Catalyst (Accelrys) (Figure 1A). Pharmacophore features used for virtual screening 
were derived from previously discovered NCX1 inhibitor flavan structures, such as ORM-10103 
(Koskelainen et al., 2003) and ORM-10962 (Otsomaa et al., 2004). Based on the results of virtual 
screening, a proposed library with 636 commercially available compounds was selected for testing in 
the fluorescence-based assay, at concentrations of 10 µM. The original hit ORM-120407 inhibited 
NCX1.1 by 87% and had an IC50 value of ~200 nM. It inhibited hERG and L-type Ca
2+ channels, with IC50 
values of 2.1 µM and 3.1 µM, respectively. These results indicated that the scaffold exhibited 
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optimization potential. The SAR of ORM-120407 was explored; thus, ORM-11372 (Table 1 and Figure 
2) was discovered during medicinal chemistry optimization. 
An analysis of 250 previously discovered NCX inhibitor compounds by Orion (Koskelainen et al., 2003; 
Otsomaa et al., 2004) resulted in a 5-feature pharmacophore, which was used for the virtual 
screening of Chambridge and Spcs compound libraries. In-silico hits were further filtered based on 
predicted activity, clogS, clogP, and diversity. The substructure features were optimized in parallel 
processes and beneficial structural features were merged, in order to identify the potential overall 
synergistic effects for NCX1.1 inhibition. Representative samples of 135 synthesized derivatives are 
presented in Figure 2.  
The hydrogen bond donor property of aniline in the original hit molecule ORM-120407 was proven to 
be important for NCX1.1 activity in the scaffold. The addition of polar substituents was not tolerated 
in the A ring, but halogen substitution on the p- and m- positions were tolerated, and resulted in 
improved NCX1 inhibition. However, neither position was favoured over the other, and none showed 
synergistic or additive effects. Their selectivity towards the hERG channel was found to be its 
differentiating property.  
SAR tolerated 5-membered B-ring systems better than 6-membered systems. Ring heteroatoms i.e. 
oxygen or nitrogen molecules at position one (of furan) in combination with a 1-, 5- substitution was 
proven to be critical for binding, i.e. a carbon at position 1 abolished activity. This finding indicates 
that the presence of a hydrogen bond acceptor at that position is important. B-ring optimization 
provided three potential ring systems that were tolerated; furans, oxazoles, and thiazoles. Two latter 
systems tolerated 4,2- and 2,4- substitutions, while the three heteroatoms in the B-ring reduced 
NCX1 inhibition activity. Though ORM-120407 showed good inhibitory activity towards NCX1, its 
selectivity towards hERG (2.1 µM) and L-type calcium (3.1 µM) channels needed to be improved. ORM-
120407 also had poor solubility (<10 µg/ml). ORM-11298 exhibited better inhibitory activity towards 
NCX1 and good selectivity towards hERG channels. The oxazole series also exhibited good selectivity 
towards L-type calcium channels such as ORM-11298, but many derivatives were chemically unstable. 
The substitution of the C-ring phenyl was unnecessary, but some substituents such as aniline and 
chlorine were tolerated. The replacement of the phenyl ring with different heteroaromatic ring 
systems was mainly tolerated. 
Synthesis 
Most compounds of were prepared via reductive amination (Figure 1C, route 1), except for ORM-
11298 and ORM-11863, which were prepared by aniline alkylation (Figure 1C, route 2). The reaction 
between the aniline and carbaldehyde derivatives could occur in the presence a strong acid at 
elevated temperatures. The reduction of the imine intermediate could be carried out using a suitable 
reducing agent, such as NaBH4. The alkylation reaction in route 2 is performed in the presence of a 
base. The products were isolated from the reaction mixture by extraction with ethyl acetate, 
followed by evaporation. The starting materials used in the processes were either commercially 
available or could be prepared via synthetic routes (Parry et al., 2003; Ye et al., 2010). ORM-11372 
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was synthesized via the reductive amination of 5-(3-nitrophenyl)furan-2-carbaldehyde with the 
corresponding fluoroaniline, followed by the hydrogenation of the nitro group under mild conditions. 
Details of experiments can be found in the supplementary material (Figures S1-S14). 
Cell lines and cell culture 
Spodoptera frugiperda (Sf9; RRID:CVCL_0549) cells are widely used for the transient and stable 
expression of recombinant proteins. Here Sf9 cells were stably transfected with human NCX 1.1 and 
maintained in spinner flasks with TNM-FH insect medium, supplemented with 10 % foetal bovine 
serum, Antibiotic-Antimycotic solution, and 50 µg/ml blasticidin at 28 oC in a non-humidified, CO2-
free atmosphere. The Sf9 cell suspension was subcultured thrice a week. 
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (Cor.4U cardiomyocytes from 
Ncardia, Germany; RRID:CVCL_Y550) were thawed, seeded onto gelatine coated coverslips, and 
maintained, as described in the manufacturer’s protocol. Cor4U cells express cardiac proteins 
including NCX1 and exhibit the relevant electrophysiology, demonstrating a potential to model human 
cardiac responses to drugs (Blinova et al., 2017; Huo et al., 2017). 
Chinese hamster ovary (CHO) cells stably expressing either hERG1a (KCNH2; RRID:CVCL_H512; from 
Sophion Biosciences, Denmark) or human 5-HT2B receptors (from Euroscreen, Belgium) were cultured 
at 37 oC in a 5 % CO2/95 % air atmosphere in the HAM F-12 medium supplemented with 10 % foetal 
bovine serum (heat inactivated), 100 μg/ml hygromycin B (Invitrogen), and 100 μg/ml geneticin or 
100 IU mL-1 penicillin and 100 IU mL-1 streptomycin, 25 mM HEPES, 500 μg/ml geneticin, and 250 
μg/ml Zeocin®. Adhered cells were detached using either Detachin® solution or trypsin and replated 
twice a week. HEK 293 (RRID:CVCL_0045) and IMR-32 (from American Type Culture Collection, CCL-
127; RRID:CVCL_0346) were cultured similarly, but maintained instead in Dulbecco’s modified Eagle’s 
medium or Eagle’s minimum essential medium, supplemented with 10 % foetal bovine serum (heat 
inactivated), 100 IU mL-1 penicillin and 100 IU mL-1 streptomycin, and 25 mM HEPES, and in the case 
of the IMR-32 cell line, with MEM non-essential amino acids. IMR-32 cells are derived from a human 
neuroblastoma and endogenously express L-type calcium channels (Sher et al., 1988). 
The IhERG cells to be studied were harvested with Detachin solution and either diluted with a volume 
of CHO-cell serum-free media (supplemented with 100 IU mL-1 penicillin/streptomycin and 25 mM 
HEPES) to obtain cells, for which the cell density was ~4 million cells mL-1  or plated on glass 
coverslips and used on the following 1-2 days. HEK 293 cells were transiently transfected using 
lipofectamine (Invitrogen, USA), with an hSCN5A (transcript variant 2)-containing plasmid, in 
Optimem medium. After a 5-hour incubation period, the transfection medium was replaced with the 
normal growth medium. The cells were harvested by trypsinisation, centrifuged, and resuspended in 
the appropriate extracellular solution for performing studies the next day. CHO-5-HT2B cells were 
plated into 96-well plates on the previous day, at a density of 40 000 cells/well, with a modified 
version of the growth media. 
Rat ventricular cardiomyocytes 
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Ethical statement. All experiments were in compliance with the Guide for the Care and Use of 
Laboratory Animals (USA NIH publication No 85–23, revised 1996), and were approved by the Csongrád 
County Governmental Office for Food Safety and Animal Health, Hungary (approval No.: 
XIII/1211/2012). The ARRIVE guidelines were adhered to during the study (NC3Rs Reporting Guidelines 
Working Group, 2010). 
Animals, housing, and husbandry. Six-week old male Wistar rats (200-250; RRID:RGD_13508588, 
obtained from a licensed supplier Toxi-coop Ltd. Hungary) were used in the study. The rats were 
maintained in standard rat cages (380 mm X 270 mm X 200 mm; ~1025 cm2). The number of cage 
companions was 4 animals/cage. Cages were equipped with external bottle-top type lids with half-
pocket wire bar lid feeders. The bedding of the cage floor was composed of aspen chips (Innovo Ltd. 
Hungary). The room temperature of the animal house was kept constant at 23 °C, with a humidity of 
40-65%. Twelve hours of dark-light cycle was applied with a low light intensity. Food (obtained from 
Innovo Ltd. Hungary) and tap water were provided ad libitum to the animals. The tap water is 
regularly checked for any pathogens.  
Cell preparation: Rats were anaesthetised with sodium thiopental (0.1 g/kg, i.p.) and injected with 
heparin sodium (500 IU i.v.). Hearts were rapidly excised, mounted via the aorta on a Langendorff 
apparatus, and retrogradely perfused at 37 oC with the Krebs-Henseleit solution for 5 min. This 
solution contained (in mM) 118.5 NaCl, 4 KCI, 2 CaCl2, 1 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, and 
11.1 glucose with a solution whose pH was maintained at 7.4, when saturated with a mixture of 
95% O2 and 5% CO2. The perfusion of the heart was continued using the Ca
2+-free Krebs-Henseleit 
solution for 10 min, and completed by the addition of 0.05% collagenase (type I), 0.05% hyaluronidase, 
and 200 µM CaCl2, for a further 10 min. Subsequently, the left ventricular myocardium was minced 
and gently agitated. Dissociated cells were stored at room temperature in a solution containing (in 
mM) 89 KOH, 70 glutamate, 15 taurine, 30 KCI, 10 KH2PO4,10 HEPES, 0.5 MgCl2, 11 glucose, and 0.5 
EGTA and the pH was set to 7.3 using KOH. Cells were rod shaped and showed a clear striation, when 
external calcium levels were restored. One drop of the cell suspension was placed in a recording 
chamber, mounted on the stage of an inverted microscope (Olympus IX51, Olympus, Japan), and the 
individual myocytes were allowed to settle and adhere to the bottom of the chamber for at least 5 
minutes before initiating superfusion. 
Fluorescence screening assay for hNCX 1.1 inhibition 
NCX reverse mode activity was stimulated via a 50% dilution of the extracellular Na+ level using the 
internal pipettor of FLEXstation, a fluorescence imaging plate reader (Molecular Devices, USA), while 
simultaneously monitoring intracellular calcium levels. After dilution concentration of other ions 
remained the same, but Na+ concentration was diluted to the half of original concentration of 172 
mM to 86 mM. For Sf9 insect cells normal extracellular Na+ ion concentration is 172 mM. Typically, 
50 µl of a solution containing 150000 – 200000 Sf9-NCX cells was loaded onto each well of a 96-well 
plate. Cells were preincubated with the intracellular calcium dye Fluo-4 and 6, and the 
concentrations of the test compound (3 replicates) were determined for about 1 h at room 
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temperature before experimentation. The extracellular solution contained (in mM) 172 NaCl, 10 
HEPES, 1 CaCl2, 1.2 MgCl2, 0.33  NaH2PO4, 5 glucose, and 5 probenecid. The pH was adjusted to 7.4 
with NaOH. The extracellular Na+ was diluted by the addition of a Na+-free extracellular solution 
(containing in mM: 147 NMDG, 10 HEPES, 1 CaCl2, 1.2 MgCl2, 0.33 NaH2PO4, and 5 glucose with the pH 
adjusted by HCl to 7.4) induced robust and reproducible intracellular calcium elevations. The 
osmolarity of both solutions was adjusted to 340 – 355 mOsm in order to match the Sf9 cell media 
osmolarity. In each plate, the IC50 determination for each test compound was based on relative 
fluorescence changes in comparison to control and 5 mM nickel acetate-induced NCX inhibition. 
Confirmatory fluorescence assay for hNCX 1 inhibition 
A confirmatory hNCX1 inhibition assay was performed in Charles River Laboratories Cleveland. Briefly 
HEK293 cells stably expressing hNCX1 were plated in 384-well black wall, clear bottom microtiter 
plates and the next day loaded with Fluo-8 for 30 min at 37 ºC. A plate was inserted into a FLIPRTETRA 
and a baseline was recorded during a pre-incubation period where test compound or vehicle in a Na+-
free HB-PS containing thapsigargin (6 µM) and FCCP (30 µM) was added to each well for ~5 min. Next 
the NCX1 stimulation period was recorded in which Na+-containing HB-PS (with 2 µM thapsigargin and 
10 µM FCCP) was added. The experiments were performed at room temperature. The kinetic data 
generated was reduced for each well to maximum relative fluorescence units (RFU) minus minimum 
RFU after subtracting bias based on the first sample. The mean of the max-min RFU values during the 
stimulation period for the 3-4 replicates at each concentration on a plate were then plotted versus 
concentration and fitted to a Hill equation. 
Fluorescence secondary screening assays 
L-type calcium channel inhibition. Undifferentiated IMR-32 cells were harvested, centrifuged and 
resuspended in a probenecid ringer consisting (in mM) 150 NaCl, 3 KCl, 1.2 MgCl2, 1 CaCl2, 20 HEPES, 
5 glucose, and 2.5 probenecid (pH 7.4 adjusted with NaOH, osmolarity 320-324 mOsm). We added 
0.04% Pluronic F-127 and Fluo-4 to this solution, and after incubating the cells for 30 min at room 
temperature, these additives were removed from the probenecid ringer via centrifugation and 
resuspension. The cell suspension was pipetted (250,000 cells in 75 μl per well) into a 96-well plate, 
into which the test compound (75 μl per well at 2,667 x the final concentration; 5 concentrations 
with 8 replicates) had already been added. The plate was centrifuged once (5 min, 1200 rpm) to 
ensure that the cells were moved to the bottom of the wells. FLEXstation was then used to measure 
the increase in intracellular calcium at 37 ºC, following depolarisation, which was induced by the 
addition (50 μl per well) of a KCl ringer containing (in mM) 200 KCl, 20 CaCl2, 1.2 MgCl2, 20 HEPES, 
and 2.5 probenecid, respectively (pH adjusted to 7.4 with KOH, with an osmolarity of 320-324 mOsm). 
Serotonin 2B receptor.  Changes in the intracellular calcium concentration of CHO-5-HT2B cells in 
the probenecid ringer were measured, using Fluo-4 or Calcium 3 dyes and the FLEXstation, at 37 ºC. 
ORM-11372 was applied at 7 concentrations (4 replicates), 10 s after the initiating the measurement 
process in the agonist assay, but was preincubated (at 8 concentrations with 3 replicates) in the 
antagonist assay, with 10 nM 5-HT added at the 10 s time point. 
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Electrophysiology 
Manual patch-clamp recordings15 of membrane currents (INCX, ICaL, INa and IhERG) were undertaken using 
either an Axopatch 200B or Axopatch ID amplifier (Molecular Devices, USA), using the whole cell 
configuration. Cells were at least initially (except when recording INa) perfused with an extracellular 
solution consisting (in mM) 143 NaCl, 4 KCl, 1.8 CaCl2, 1.2 MgCl2, 5 glucose, and 10 HEPES (pH 7.4 
with NaOH; osmolarity adjusted to 301 ± 3 mOsm). A slightly modified version was used for the rat 
ventricular cardiomyocytes (i.e.in mM: 144 NaCl, 0.4 NaH2PO4, 4.0 KCl, 1.8 CaCl2, 0.53 MgSO4, 5.5 
glucose, and 5.0 HEPES). Patch pipettes were pulled with a P-2000 or P-97 micropipette puller (Sutter 
Instruments, USA) from borosilicate glass capillaries and had resistances of between 2 and 4 M when 
filled with any of the pipette solutions (see below). The data was filtered at 1 or 2 kHz and digitised 
at 10 kHz with acquisition and analysis performed by use of pClamp software (versions 8-10; Molecular 
Devices; RRID:SCR_011323). 
Measurement of NCX current (INCX). After the establishment of the whole cell configuration with 
hiPSC derived cardiomyocytes or rat ventricular myocytes the extracellular solution was switched to 
a K+-free bath solution as described earlier (Hobai et al., 1997; Jost et al., 2013). The solution was 
composed (in mM) 135 NaCl, 10 CsCl, 1 CaCl2, 1 MgCl2, 0.2 BaCl2, 0.33 NaH2PO4, 10 TEACI, 10 HEPES, 
and 10 glucose supplemented with 20 µM ouabain, 50 µM lidocaine, and 1 µM nisoldipine or 2 µM 
nitrendipine at pH 7.0 (osmolarity adjusted to 301 ± 3 mOsm). The pipette solution contained (in mM) 
140 CsOH, 75 aspartic acid, 20 TEACI, 5 MgATP, 10 HEPES, 20 NaCl, 20 EGTA, and 10 CaCl2 (pH 
adjusted to 7.2 with CsOH; osmolarity adjusted to 290 ± 2 mOsm). The free intracellular Ca2+ level in 
the patch pipette was 140 nM according to Maxchelator (RRID:SCR_000459) software (Bers et al., 
2010). 
The measurement of current in the K+-free bath solution using a ramp voltage protocol at 20 s 
intervals represented the first control, after which values were measured in the presence of one or 
more increasing concentrations of ORM-11372, and finally upon exposure to 10 mM NiCl2. The voltage 
protocol consisted of voltage ramps (at a rate of 100 mV/s) with a holding potential of -40 mV to 60 
mV, which changed to -100 mV and then reverted back to -40 mV. INCX was defined as the Ni
2+-sensitive 
current value; however, for rat ventricular myocytes, the magnitude of the inward current (forward 
mode) was particularly small and variable. Therefore, to enhance the inward current and enable a 
solution with a certain concentration of ORM-11372 to be measured, the concentrations of the K+-
free and pipette solutions were altered. In the bath solution, the CaCl2 concentration was reduced 
to 0.5 mM, while in the pipetted solution, the NaCl and EGTA concentrations were decreased to 5 
and 10 mM, respectively. All experiments were performed at 35-37 oC. The outward human INCX 
inhibition current was measured at the following ORM-11372 concentrations: 3 (n = 4), 10 (n = 6), 30 
(n = 4), and 100 (n = 3) nM. The concentrations used for human inward INCX current measurement were 
3 (n = 4), 10 (n = 4), 30 (n = 3), and 100 (n = 2) nM. The outward INCX current in rat cardiomyocytes 
was measured at concentrations ranging from 1 to 1000 nM (n = 5). The inward INCX current in rats 
was measured in additional experiments under changed conditions, to enhance the inward INCX 
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current. In these experiments (n = 3), the effect of ORM-11372 was tested at a concentration of 10 
nM, at which the IC50 and reverse INCX current values were approximately equal. 
Measurement of L-type calcium current (ICaL). ICaL was recorded from hiPSC-derived cardiomyocytes 
(at room temperature, n = 2) and rat ventricular myocytes at 1 µM (n = 3; 5 cells) and at 10 µM (n = 
4; 6 cells) in an extracellular solution supplemented with 3 mM of 4-aminopyridine at 37 oC. The 
pipette solution used for hiPSC-derived cardiomyocytes consisted (in mM) (pH 7.2; osmolarity 
adjusted to 293 mOsm) 110 KCl, 40 KOH, 20 TEACI, 3 MgATP, 10 EGTA, and 5 HEPES. The composition 
of the pipette solution used for rat cardiomyocytes was (in mM) 125 CsCl, 20 TEACI, 5 MgATP, 10 
EGTA, and 10 HEPES; the pH was adjusted to 7.2 using CsOH. ICaL was evoked by a 400 ms 
depolarization process to 0 mV from a holding potential of -40 mV every 5 s, or in the case of the rat 
cardiomyocytes, by 400 ms; depolarizations to potentials ranging from -35 mV to 55 mV occurred 
after a prepulse to -40 mV, from the holding potential of -80 mV. 
Measurement of NaV1.5 current (INa). Recordings were performed on HEK cells (n = 3) that transiently 
expressed SCN5A at room temperature, in a bath solution containing (in mM) (pH 7.4 with N-methyl-
D-glucamine; osmolarity adjusted to 300 ± 2 mOsm) of 40 NaCl, 97 L-aspartic acid, 4 KCl, 1.8 CaCl2, 
1 MgCl2, 10 glucose, and 10 HEPES. The pipette solution contained (pH 7.2 with CsOH; osmolarity 
adjusted to 270 ± 3 mOsm) 130 caesium methane sulfonate, 5 MgCl2, 5 EGTA, 0.1 GTP, 4 Na2ATP, and 
10 HEPES. The voltage protocol, which was repeated after each second, included of the process of 
hyperpolarisation, from a holding potential of –80 mV to -120 mV for 200 ms, followed by that of 
depolarisation to -15 mV for 10ms. The peak current values observed while applying the test pulse at 
-15 mV were used for analysis.  
Measurement of KV11.1 current (IhERG). Values from hERG expressing cells (n = 4) were recorded 
with the standard extracellular solution at the physiological temperature and a pipette solution 
containing (in mM) 130 KCl, 7 NaCl, 5 EGTA, 1 MgCl2, 5 Na2ATP, and 5 HEPES (pH was set to 7.2 with 
KOH; osmolarity was adjusted to 290 ± 3 mOsm). IhERG was evoked using a voltage protocol, which 
was repeatedly performed every 10s, consisting of a depolarisation step from the holding potential 
of –75 mV to 10 mV for 500 ms, followed by a repolarisation step to –40 mV for 500 ms. The peak tail 
current values at –40 mV were used for analysis. 
In addition, after loading the CHO-hERG cell suspension, whole cell voltage-clamp values were 
recorded at room temperature on a QPatch 16x automated patch-clamp (Sophion Biosciences), in the 
single-hole mode. ORM-11372 solutions with concentration of 0.3 (n = 4), 1 (n = 5), 3 (n = 8), 10 (n = 
8), and 30 µM (n = 8) were studied. The extracellular solution contained (in mM) 145 NaCl, 4 KCl, 2 
CaCl2, 1 MgCl2, 10 glucose, and 10 HEPES (pH 7.4 with NaOH; osmolarity adjusted to 305 mOsm). The 
intracellular recording solution contained (in mM) 120 KCl, 1.75 MgCl2, 5.37 CaCl2, 4 Na2ATP, 10 EGTA, 
and 10 HEPES (pH 7.2 with KOH; osmolarity adjusted to 295 mOsm).The voltage protocol, which was 
repeated every 10 s, included a 200 ms step to change the holding potential from –80 to -50 mV, to 
measure the leak current, and further depolarization to + 20 mV for 2 s, followed by a repolarization 
to –50 mV for 2 s. The hERG tail current was measured as the difference between the peak tail current 
amplitude during the repolarization step and leak current measurement step. Subsequently, the 
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voltage-dependence of the block was also assessed, by carrying out depolarization for 4 s, from –80 
mV to +60 mV in 10 mV steps, before and after the addition of 20 µM ORM-11372 (n = 7). The peak 
tail current elicited during the 5 s repolarization step to –50 mV was measured and plotted against 
the preceding depolarization step voltage values. 
Action Potentials. Action potentials were recorded in spontaneously beating Cor.4U cardiomyocytes 
in the current-clamp using the perforated patch technique and voltage-sensitive dye (di-4-ANEPPS), 
in a 96-well plate format. The latter ratiometric optical measurements were performed on the 
CellOPTIQ platform at Clyde Biosciences (Newhouse, UK). The patch-clamp measurements used the 
standard extracellular solution at the physiological temperature and a pipette solution containing (in 
mM) 122 K-gluconate, 30 KCl, 1 MgCl2, and 5 HEPES (pH 7.2 with KOH; osmolarity adjusted to 290 ± 
3 mOsm), and 0.24 mg/ml of amphotericin B. The patch-clamp data shown is from cardiomyocytes 
(n = 4) that exhibited ventricular-like action potentials, i.e. a ratio (time difference between APD30 
and APD40/time difference between APD70 and APD80) >1.5 (Ma et al., 2011).  
Selectivity Panel. Radioligand binding assays were performed at Eurofins Cerep SA (Celle 
L’Evescault, France), for testing the inhibition capacity of ORM-11372 (at 10 µM with 2 replicates), 
in over 75 targets. These included receptors (e.g. human A1, A2A, and A3 adenosine receptors; α1 and 
α2 adrenergic receptors; human β1-β3 adrenergic receptors; human D1, D2S, D3, D4.4, and D5 dopamine 
receptors; EGF and VEGF receptors; human M1-M5 muscarinic acetylcholine receptors; human 5-HT1A, 
5-HT2A, 5-HT2B, 5-HT2C, 5-HT4e, 5-HT5A, 5-HT6, and 5-HT7 serotonin receptors), ion channels (5-HT3, 
Ca2+, KATP, KV, SKCa, Na
+, and Cl−), and transporters (adenosine, norepinephrine, dopamine and 
serotonin). Follow-up functional studies (with 5 concentrations and 2 replicates) were performed for 
5-HT2A and the norepinephrine transporter. Agonism and antagonism at h5-HT2A was explored in 
recombinant HEK 293, and intracellular calcium changes were detected using fluorimetry. 
Norepinephrine uptake was measured by carrying out scintillation counting of [3H]NE incorporated 
into rat hypothalamus synaptosomes. 
Design and analysis for isolated heart preparations and in vivo 
experiments 
Donor Heart Procurement: All the human hearts used for this study were obtained after legal 
consent was provided by organ donors in the US. The policies for donor screening and consent were 
the same as those established by the United Network for Organ Sharing (OPTN, 2019). Organizations 
supplying human tissues to AnaBios follow the standards and procedures established by the US Centers 
for Disease Control, and are inspected biannually by the Department of Health and Human Services. 
Tissue distribution is governed by internal IRB procedures and was compliance with HIPAA regulations 
(Edemekong et al., 2019) regarding patient privacy. All organ donor transfers to AnaBios are fully 
traceable and periodically reviewed by US Federal authorities. In general, AnaBios obtains donor 
hearts from adults aged 17–60 years old. Though some donors were trauma victims, donors with the 
following conditions were excluded: ejection fraction < 45%, HIV, cardiac death, HBV, congenital LQT 
syndrome, HCV, LOT syndrome, MRSA, downtime >20 min, ongoing infections, positive blood cultures 
without treatment and 48-h result data. Donor hearts from 1 male and 1 female (both 57 years old, 
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Table S5) were harvested using AnaBios’ proprietary surgical techniques and tools, and were shipped 
to AnaBios via dedicated couriers. Upon arriving at AnaBios, each heart was assigned a unique 
identifier number that was reproduced on all relevant medical history files, data entry forms, and 
electronic records. 
Recording of Action Potentials in Human Ventricular Trabeculae: Procedures used for tissue 
dissection and recording were similar to those described previously (Page et al., 2016). Briefly, the 
human heart was transferred into a dissection vessel containing a cold (4°C), fresh proprietary 
dissection solution. The heart was completely submerged into the dissection solution. Ventricular 
trabeculae were dissected and transferred to the recording chamber. The approach used to record 
action potentials (APs) is similar to that described by Page et al (Page et al., 2016). Briefly, a single 
tissue was mounted into the experimental chamber filled with oxygenated Tyrode’s external solution, 
containing (in mM) 136 NaCl, 4 KCl, 0.5 MgCl2, 12 NaHCO3, 0.35 NaH2PO4, 11.1 dextrose, 1.8 CaCl2, 
and 10 HEPES (pH 7.4). The temperature of the solution was maintained at 37°C, at a flow rate of 5 
mL per minute. The tissue was allowed to equilibrate for 30-60 min, while providing stimulation (3 
V, 3 ms) at a frequency of 1.0 Hz. High impedance borosilicate microelectrodes were prepared with 
a tip resistance of 10-20 MΏ, filled with 3 M KCl. Upon tissue impalement, the membrane potential 
was allowed to stabilize (typically, around -85 mV). Tissues with resting membrane potentials more 
positive than −75 mV were rejected. Bipolar stimulation at 1.5x threshold was applied, and recordings 
were obtained in the continuous mode with sampling at 20 kHz, using ADInstruments and LabChart 
Software. Tissue exclusion criteria included the following: (1) interruption of perfusion/oxygenation; 
(2) absence of APs following stimulation at baseline; (3) time frame of drug exposure not respected; 
(4) unstable response to stimulation at baseline; (5) resting membrane potential (RMP) > −75 mV; (6) 
maximal amplitude of AP (AMAX) < 70 mV; and (7) AP duration at 90% repolarization (APD90) < 200ms 
or >450 ms. ORM-11372 was evaluated at 3 concentrations in 4 ventricular trabeculae derived from 2 
donor hearts (n=2, two replicates). Testing concentrations were 0.1, 1, and 10 mM. Following the 
stabilization of each tissue, APs were collected and assessed for 31 min in the vehicle control solution 
(Tyrode with 0.1% DMSO), at stimulation frequencies of 1 Hz for 25min, 2Hz for 3 min, and 1Hz for 3 
min. Following this vehicle control period, 3 concentrations of ORM-11372 were applied sequentially 
and cumulatively. Each concentration was applied for 31 min with the same stimulation sequence as 
in the vehicle controls. 
Animal experimental design and analysis 
All animal experiments were performed according to European Community Guidelines for the use of 
experimental animals and approved by the Finnish National Animal Experiment Board. All studies 
complied with the ARRIVE guidelines (NC3Rs Reporting Guidelines Working Group, 2010). 
Selection of animal species: The rat is the most widely used rodent species in toxicology studies 
performed for drug development. The Sprague-Dawley rat strain (RRID:RGD_70508) is commonly used 
in the rat myocardial infarction (MI) model (Fishbein et al., 1978). However, the functional similarity 
between the Ca2+ handling proteins (including NCX) in rats (Bassani et al., 1994) and human hearts is 
rather low. The Ca2+ circulation balance in the guinea-pig and rabbit hearts are more similar to that 
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of a human (Milani-Nejad et al., 2014). Rabbits and humans are also known to react similarly to 
medication; hence, the rabbit was selected as a nonrodent species. 
Housing and husbandry: Animals were monitored daily by laboratory personnel. If the general health 
status of an animal was significantly worsened, the animal was sacrificed with an overdose of 
pentobarbital. Human endpoints included no spontaneous movements and inability to drink or eat 
during the 24-h observation period, massive bleeding, spontaneous inflammation, missing anatomical 
features or swelling, and breathing difficulties. Specific pathogen-free animals were housed in half-
barrier rooms where special protective clothing was required by personnel. Animal rooms were 
cleaned regularly 3 times per week and cages and bottles were changed at regular intervals once a 
week. The temperature was maintained at 22 ± 2°C and humidity at 55 ± 15%. In the light-dark cycle, 
lights were kept on from 06.00 to 20.00 h. Body weights of all animals were measured weekly. 
Randomization and blinding: Randomization was used whenever feasible. Guinea-pigs were 
randomized into vehicle and ORM-11372 groups for in vitro contraction force measurement from 
papillary muscle. In hemodynamic studies involving rabbits, only one study group was used, according 
to the 3R principle. Because the experimental setup involved ascending doses in one study group, 
randomization was impossible. Baseline values were used as controls to reduce variability. However, 
the MI rat model required the inclusion of two study groups, to eliminate the effect of surgical 
operations. The MI study setup enabled the use of randomization. The study duration for anestetised 
animals is limited; hence, higher doses had to be administered, which required blinding to be 
performed in all in vivo studies. The blinding was not considered relevant, because measured 
absolute values and derivated parameters are not sensitive to biased interpretations. 
In vitro contraction dynamics measurement 
Guinea-pigs (both sex, body weight ranging 342-565 g, Dunkin Hartley, M&B A/S, Ry, Denmark) 
were used in the study. The animals were housed in solid bottom polycarbonate cages (Makrolon® 
IV, 385 x 590 x 200 mm) with stainless steel wire mesh lids, up to three animals of same sex per 
cage. Autoclaved aspen chips (Tapvei Ky, Kaavi, Finland) were used as bedding. A commercially 
available rodent SDS FD1 (P) SQC pellet diet (Special Diet Services Ltd, Witham, England) and tap 
water from the public supply (Espoon vesilaitos, Espoo, Finland) were available ad libitum in 
polycarbonate bottles (800-1000 ml) with plastic cabs (Scanbur A/S, Ejby, Denmark). 
Guinea-pigs will be killed by a blow on the skull and the heart will be excised. Right ventricular 
papillary muscle will be dissected and rinsed in ice-cold Tyrode solution. Thereafter, the papillary 
muscle will be mounted for the measurement of twitch tension in an organ bath containing 
modified Tyrode solution (at 37°C) bubbled with carbogen (95% O2, 5% CO2). The composition of the 
Tyrode solution will be the following (mM): 135 NaCl, 1 MgCl2 x 6H2O, 5 KCl, 2 CaCl2 x 2H2O, 15 
NaHCO3, 1 Na2HPO4 x 2H2O, 10 glucose at pH 7.3-7.4. 
The signal was acquired with a validated acquisition system ACFO v1.0 (Fision Oy, Finland). The 
following parameters were measured: twitch tension (Tw), rest tension (RT), time to peak tension 
 
 
This article is protected by copyright. All rights reserved. 
(TTP), and half relaxation time (HRT). At steady state, 15 twitch tensions were acquired and 
averaged was used for statistics. 
The baseline twitch tensions were measured after a stabilization period of 20-40 min. Thereafter, 
vehicle (1.1% DMSO) or ORM-11372 in the Tyrode solution were superfused into the cuvette for 15 
min and the effects were measured from the steady state level. All experiments were carried out 
at 37°C. 
Experimental of myocardial infarction model 
Male Sprague-Dawley rats (Harlan, Netherlands B.V.) were housed in polycarbonate cages (Makrolon® 
IV with stainless steel wire mesh lids). A maximum of 5 rats were housed per cage with aspen chip 
bedding (Tapvei Ky, Kaavi, Finland). Rats had free access to water (twice filtered, Espoon Vesi) and 
a rodent diet (SDS RM1 (P) SQC pelleted diet, Special Diet Services Ltd, Witham, England). The 
acclimation period before experiments was at least 5 days. In the myocardial infarction model, rats 
(7-8 weeks, 200-250 g) were randomised into either the myocardial infarction or sham groups. In this 
weight range, a rat is considered a young adult, when its evolution phase is characterized by slow 
growth and its surgical mortality is lower than that of older animals. Male rats were used to minimize 
the variability of the cardiac response to several stimuli (Zornoff et al., 2009). 
Rats were anesthetized with a combination of ketamine (Ketalar® 50 mg/kg i.p.) and medetomidine 
(Domitor 250 µg/kg i.p.), intubated, and artificially ventilated with air (Ugo Basile 7025). A 
myocardial infarction (MI) was induced by the occlusion of the left coronary artery under aseptic 
conditions (Levijoki et al., 2001; Selye et al., 1960). The left coronary artery was ligated at a distance 
of about 2-3 mm from the origin of the aorta with a silk suture and the heart was repositioned into 
the chest. After ligation, the wound was closed carefully. The muscle layer was closed with soluble 
stitches and skin layers with insoluble stitches, followed by a partial reversal of anesthesia via the 
intraperitoneal administration of atipamezole (Antisedan® 0.3 -1 mg/kg i.m.). The trachea tube was 
removed, and the trachea and underlying muscle and skin layers were closed immediately. To prevent 
dehydration, rats were subcutaneously administered 5 ml of 0.9% NaCl. After surgery, rats were pain-
medicated with buprenorphine for at least two days (0.05 mg/kg s.c. twice a day). For sham-operated 
rats, the same procedure was performed, without ligation. Rats were analysed for 7 days after the 
myocardial infarction (MI), for severe acute heart failure development e.g. oedema or breathing 
difficulties. 
Hemodynamic measurements of anesthetized animals 
All animals were administered multiple ascending infusion doses of ORM-11372; blinding was not 
possible. Systemic blood (SP) and left ventricular pressure values (LVPs) were measured with pressure 
transducers (SP for femoral artery: Isotec, Hugo Sachs Elektronic, Germany; a miniature pressure 
transducer Mikro-Tip transducer SPR-249, Millar Instruments was inserted into the left ventricle via 
the right carotid artery). The signal was amplified (DC-bridge amplifier type 660, Hugo Sachs 
Elektronik, Germany), digitised (I/O connector block type SCB-68, National Instruments, USA), 
 
 
This article is protected by copyright. All rights reserved. 
recorded, and analysed (IHME 1.0.9, Fision Ltd, Finland). Left ventricular inotropic effect (LV 
+dP/dtmax), relaxation (LV -dP/dtmin), and heart rate (HR) values were analysed from LVP signals.  
At the end of the hemodynamic experiments, rats and rabbits were killed with an overdose of 
pentobarbital. Small laboratory equipments (forceps, scissors, scalpels, etc.) were sterilized in the 
glass bead sterilizer at 300°C for 10 sec (10 sec). 
The blood pressure waveform was measured continuously in milliseconds. The blinding was not 
considered relevant, because the absolute value was not sensitive to biased interpretations, and all 
parameters are derived from of them. 
Haemodynamics in MI rats: Haemodynamics were assessed 7 days after a myocardial infarction (n=6) 
or sham operation (n=6) as follows. Rats were anesthetized with isoflurane (2.25-2.5 %, Baxter) in 
carbogen (95 % O2 and 5 % CO2) and nitrous oxide (1:1), using a small rodent ventilator (Ugo Basile 
7025, ~10 ml/kg, 60 strokes/min). The rats were infused with 0.9 % NaCl in the carotid vein at the 
stabilization and baseline levels. ORM-11372 was administered into MI (n=6) and sham (n=6) rats in 
ascending infusion doses of 1.7, 17, 167, and 417 µg/kg/min. Infusions were administered into the 
jugular vein of MI rats at the infusion rate of 5 ml/kg/h (Terumo TE-311, Belgium). Doses were 
selected based on a pilot study with healthy rats (Figure S20). The total number of animals in the 
study was 12+2, due to the replacement of two MI rats. One MI rat died while administering 
anesthesia, as infarcted animals are sensitive to anesthesia, and another MI rat was excluded due to 
the dosing error indicated by the bioanalysis of plasma samples (no ORM-11372 concentration 
observed in plasma). 
After hemodynamic assessments, the anesthetized rats were killed with an overdose of pentobarbital 
(2 ml of Mebunat® vet 60 mg-ml per rat). The entire heart of each animal was fixed in buffered 4% 
formaldehyde solution, trimmed, processed, and embedded in paraffin. The hearts were cut 
horizontally at three different levels: apex, mid part, and base. Sections with a thickness of 4 µm 
were cut from each level stained with haematoxylin and eosin, for general histopathological analysis. 
Infarct sizes were determined using picrosirius red staining as an indicator of cardiac fibrosis, and 
the size was measured using Analysis Pro software. The infarct area was calculated as the percent of 
fibrotic tissue in the total myocardial area (mean of three levels).  
Haemodynamics in rabbits: Male New Zealand white rabbits (Harlan, Netherlands B.V.) were housed 
individually in polycarbonate cages (Scanbur number 8 plastic cages with stainless steel door) with 
aspen bedding (Aspen Bricks M, Tapvei Ky, Kaavi, Finland). The acclimation period before 
experiments was at least 21 days. Rabbits weighing 2.0-2.3 kg (age 10-12 weeks) were used for 
hemodynamically assessing ORM-11372 (no randomisation, baseline values as own control). The diet 
provided to rabbits was SDS Stanrab (P) SQC pelleted (Special Diet Services Ltd, Witham, England). 
Water was provided ad libitum in polycarbonate bottles (750 ml). 
Rabbits (n=5) were sedated with intravenously (marginal vein) injected diazepam (2 mg/kg, Diapam®, 
Orion Pharma). Anesthesia was inducted with intravenous s-ketamine (10-20 mg/kg Ketanest-S®, 
Pfizer) and maintained with a s-ketamine intravenous infusion (15-80 mg/kg/h). Animals were placed 
on a heating table (+38°C) and tracheas were cannulated. Rabbits were ventilated via a rodent 
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ventilator (Ugo Basile type 7025, Hugo Sachs Elektronik, Germany; respiratory volume 10 ml/kg, 30 
strokes per min for rabbits). ORM-11372 was administered into the jugular vein at an infusion rate of 
10 ml/kg/h (Terumo TE-311, Belgium), at infusion doses of 17, 167, and 833 µg/kg/min. 
Blood sampling for bioanalysis 
At the end of each infusion process, blood samples (300-500 µl) added to a chilled EDTA polypropylene 
tube (CapiJect®, Terumo) and centrifuged (4000 rpm, 10 min, at 4°C). Plasma was immediately 
frozen in polypropylene tubes and stored at –20°C. ORM-11372 was extracted from plasma samples 
using a liquid–liquid extraction process and analysed using liquid chromatography–tandem mass 
spectrometry (Agilent Technologies series 1100 liquid chromatographic system and a Sciex LC-MS/MS 
API 4000 mass spectrometry). The lower limit of quantification for the plasma concentration of ORM-
11372 was 32.0 ng/ml. Plasma protein binding in ORM-11372 was assessed using the TRANSIL High 
Sensitivity kit, as per the manufacturer’s instructions (Sovicell, GmbH, Germany). 
Materials 
Study substance: ORM-11372 was synthetized by Orion Pharma. To perform in vitro experiments, 
ORM-11372 was dissolved in dimethyl sulphoxide (DMSO), to obtain a 10 mM stock solution. Spiking 
solutions were prepared daily by diluting the stock solution with DMSO, and used to prepare the final 
drug solutions with certain concentrations by diluting them with extracellular solutions (the vehicle 
concentration was either 0.1 or 0.3 %). The solubility of ORM-11372 in saline and 5% glucose solutions 
used for in vivo dosing were were 5.3 mg/ml and 5.4 mg/ml, respectively. ORM-11372 was soluble in 
10 – 100 µg/ml of phosphate buffer (in pH 7.4). ORM-11372 has the following drug like properties: 
the number of hydrogen bond acceptors is 1 (<10) and donors is 3 (<5), molecular weight of free base 
is 282 (<500), and the predicted logP value is less than 5 (ADMET Predictor: 3.95, MOE: 3.413, QikProp: 
3.974). 
Chemicals: Isoflurane (Forane®, Baxter), atipamezole (Antisedan®, Orion Pharma), medetomidine 
(Domitor®, Orion Pharma, ketamine (Ketalar®, Pfizer Oy Animal Health, lipofectamine (Invitrogen, 
USA), hygromycin B (Invitrogen), buprenorphine (Temgesic®, INDIVIOR UK Ltd). All other chemicals 
and cell culture media were obtained from Sigma-Aldrich. 
Cell lines and cell culture: NCX 1.1 was cloned and plasmid was constructed by Orion Pharma 
Spodoptera frugiperda (Sf9) cells (ATCC), human induced pluripotent stem cell (iPSC) derived 
cardiomyocytes (Cor.4U cardiomyocytes from Ncardia, Germany), DetachinTM Cell Detachment 
Solution, Genlantis), HEK 293 cells and IMR-32 human neuroblastoma cells (ATCC), CHO cells hERG1a 
(KCNH2; Sophion Biosciences, Denmark), CHO cells human 5-HT2B receptors (Euroscreen, Belgium), 
hSCN5A plasmid (OriGene Technologies Inc., Rockville, MD, USA). 
Data and Statistical Analysis 
Data Analysis of human trabeculae: For each frequency tested, the last 30 APs acquired at the end 
of the period were averaged for vehicle controls, for each ORM-11372 solution with a certain 
concentration. Analysis at 1 Hz included only the last 30 APs from the initial 25 min incubation period. 
The following AP parameters and pro-arrhythmia variables were analysed offline upon the completion 
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of recordings: RMP (mV), AMAX (mV), AP duration at percent repolarization (APD30, APD50, APD90) 
(ms), short term variability analysis of AP duration (STV), triangulation (APD90-APD30). 
STV was calculated as the beat-to-beat variability in repolarization from APD90 Poincare plots over 
a 30 sec duration. STV for APD90 was calculated as follows: STV= ⅀|APDn+1−APDn|/(30×√2), where 
APD (n) and APD(n+1) are the APDs for the nth AP and the following AP, respectively. 
The effects of ORM-11372 were quantified relative to the data collected during the vehicle control 
period. Threshold values for changes over the baseline control for APD30, APD50, APD90, 
triangulation, and STV at 1 and 2 Hz pacing frequencies have been determined in a previous validation 
study (Page et al., 2016). Results are expressed as mean ± standard error values of the mean (SEM). 
The data and statistical analysis of in vitro and in vivo studies comply with the recommendations 
for experimental design and analysis in pharmacology.(Curtis et al., 2018). Statistical analysis were 
done only where number of independent samples was 5 or more. A p-value of <0.05 was considered 
to be significant. Two-way repeated measures ANOVA were used for the analysis of the papillary 
muscle and myocardial infarction models. One-way repeated measures ANOVA was used for the rabbit 
hemodynamic study. The Sidak posthoc-test was run only if the F-value was statistically significant, 
and there was no significant variance in homogeneity. Data is presented as mean ± SEM. Prism 8.0.2 
(GraphPad Software Inc., San Diego, CA, USA; RRID:SCR_002798) was used for statistical analysis. 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2019/20 (Alexander et al., 2019). 
Results 
ORM-11372 concentrations dependently inhibited the increase in intracellular calcium in insect cell 
line expressing human NCX1.1. The insect cell line was used as the screening assay. The IC50 for the 
inhibition of NCX in the reverse mode was 6.2±0.4 nM. 
The potency of ORM-11372 for NCX was subsequently studied using the whole-cell patch-clamp 
technique in human iPS-derived cardiomyocytes (hiPSC-CMs; Figure 3) and rat ventricular 
cardiomyocytes (Figure 4). The solutions and experimental protocol used to measure the bidirectional 
NCX current (INCX) was identical for both preparations. As shown in Figure 3A, the current was 
recorded in response to repetitive voltage ramp pulses first in a K+-free bath solution after blocking 
Na+, Ca2+, K+, and Na+/K+ pump currents, to yield the baseline, and during the addition of ORM-11372. 
Finally, when the highest concentration of ORM-11372 had reached a steady state, 10 mM NiCl2 was 
added to completely block INCX. Examples of individual trace currents under different conditions are 
shown for a hiPSC-CM in Figure 3B and for a rat cardiomyocyte in Figure 4A. ORM-11372 decreased 
both the outward and inward currents. The IC50 values for the outward and inward INCX (i.e. the Ni
2+-
sensitive current) of hiPSC-CMs were 4.8 and 5.6 nM, respectively (Figure 3C). In rat primary 
ventricular cardiomyocytes, the magnitude of outward INCX (the reverse mode) with an IC50 of 11.3 
nM (Figure 4B) was reduced in an ORM-11372 concentration-dependent manner. It was difficult to 
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record inward INCX (the forward mode) from rat cardiomyocytes; hence, the experimental conditions 
were altered, to enhance its magnitude (see Methods). At 10nM, the approximate IC50 on the outward 
INCX, ORM-11372 inhibited inward INCX by 53.8±3.9 %. 
Comparison with known NCX inhibitors 
Further confirmation of the inhibitory effects of ORM-11372 was sought in the hNCX1 fluorescence 
calcium flux assay available at Charles River. In experimental conditions increasing intracellular 
calcium (by the presence of thapsigargin and FCCP) and eliciting NCX forward mode activity 
(switching from Na+-free to Na+-containing buffer), ORM-11372 concentration-dependently inhibited 
the calcium efflux signal (Figure 5A) with an IC50 of 142 nM and 164 nM (0.3 % and 1 % DMSO 
respectively; NS). The hNCX1 antagonist of five other compounds was also assessed in this assay. 
ORM-11372 was the most potent inhibitor (Figure 5B) followed by ORM-10962 (Figure 5C), ORM-10103, 
SEA0400, KB-R7943, and lastly SN-6 whose IC50 appears >100 µM. 
Selectivity 
The functional selectivity of ORM-11372 towards the L-type Ca2+ channel was first tested with the 
IMR-32 neuroblastoma cell line, using fluorometric images of intracellular changes in calcium levels. 
Depolarisation of undifferentiated IMR-32 cells by KCl addition induced an increase in intracellular 
calcium levels, which can be suppressed by preincubation with verapamil or the 1,4-dihydropyridine 
nicardipine (Sher et al., 1988). L-type calcium channels mediated changes in intracellular calcium 
levels, and these were concentration dependently inhibited by an ORM-11372 solution with an IC50 of 
6.1 µM. Further electrophysiological studies were then performed with hiPSC-CMs and rat ventricular 
cardiomyocytes. The inward ICaL was reduced by 1 µM ORM-11372 at 0 mV by 14.1 % in hiPSC-CMs 
(Figure 6A), and a 7.8 % inhibition was observed in rat cardiomyocytes (Figure S16A-B; Individual 
inhibition values at 1 and 10 µM are shown in Table S3 and S4, respectively). However, when rat 
ventricular cardiomyocytes were exposed to ORM-11372 at a concentration of 10 µM, ICaL was 
significantly decreased (Figure S16C). ICaL inhibition exhibited voltage dependency, and was greater 
(59-69 % versus 36-39 %) at more negative activating test potentials (-35 to -20 mV versus 0 to 40 
mV). 
The effect of ORM-11372 on other cardiac ion channel currents were investigated. The reduction in 
the human KV11.1 current (IhERG) was initially examined using stably expressing cells on an automated 
patch-clamp instrument, and then with the manual patch-clamp. ORM-11372 concentration 
dependently inhibited IhERG (Figure 6B); IC50 values were 19.2 and 10.0 µM, using the automated and 
manual patch-clamp methods, respectively (Figure S15A). ORM-11372 significantly altered the 
voltage dependency of the IhERG activation curve (Figure S15C) and displayed significant voltage 
dependent blockage. While IhERG inhibition was minimal at –30 and –20 mV, inhibition increased 
markedly at –10 and 0 mV, and reached a steady state between 10 and 60 mV, i.e. at potentials 
where the channels were fully activated (Figure S15D). Additionally, ORM-11372 concentration 
dependently inhibited human the NaV1.5 current (Figure 6C), with an IC50 value of 23.2 µM.  
ORM-11372 increased twitch tension by 146 ± 32% vs. 7 ± 5% in vehicle group (Figure 6D), but did 
not increase rest tension (-8 ± 2% vs. -10 ± 1% in vehicle, Figure 6E), did not affect time to peak (-4 
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± 1% vs. -5 ± 2% in vehicle, Figure 6F) nor half relaxation time (8  ± 9% vs. 11 ± 4% in vehicle, Figure 
6G). 
The selectivity profile of ORM-11372 was additionally evaluated in binding assays for a diverse panel 
of targets. While minor effects such as those for the Na+/K+-ATPase or ryanodine receptor (11 % and 
15 % inhibition) were seen, with a screening concentration of 10 µM, specific ligand binding inhibition 
was significant(i.e. >50 %) at the peripheral benzodiazepine receptor, imidazoline I2 receptor, 
serotonin 2A and 2B receptors, and norepinephrine transporter. The latter three targets were studied 
functionally. The uptake of norepinephrine into rat hypothalamus synaptosomes was inhibited by 
ORM-11372 in a concentration-dependent manner; the IC50 value was 1.7 µM. Neither agonism nor 
antagonism was seen with ORM-11372 (maximum concentration: 10 µM) at 5-HT2A. Similarly, no 
agonism was evident at 5-HT2B; however, 10 µM ORM-11372 moderately inhibited (38 %) the 5-HT2B-
mediated increase in intracellular calcium evoked by 10 nM serotonin. 
Human ventricular trabeculae 
ORM-11372 caused no significant changes in APD30, APD50, and APD90 values up to a concentration of 
10 µM, at both 1 and 2 Hz pacing frequencies. However, there was a trend in the reduction in APD, 
particularly APD30, at 1Hz (Figure S17); this seemingly contrasts with the significant shortening of 
hiPSC-CM APD by ORM-11372 (at 0.1 or 0.3 µM; Figure S18). As expected, the effect of the positive 
control (0.1 μM dofetilide) was observed in trabeculae tested with ORM-11372 (Figure 7; individual 
values are shown in Figure S17 (Page et al., 2016; Qu et al., 2017). Moreover, ORM-11372 showed no 
effects on STV and triangulation, two pro-arrhythmia markers that are used to identify pro-
arrhythmic risk (Page et al., 2016; Qu et al., 2017), at a pacing rate of 1 or 2 Hz, at any tested 
concentration (Individual values in Figure S19). However, the addition of 0.1 μM dofetilide to the 
trabeculae tested with ORM-11372 increased STV and triangulation (Figure S18). Taken together, 
these data clearly suggest that ORM-11372 can be classified as devoid of pro-arrhythmic risk. 
In vivo haemodynamics in rat myocardial infarction (MI) model 
Infarcted areas were 14.5±1.8% and 1.1±0.6% in the MI and sham-operated groups, respectively 
(Figure S20). Percentage changes are calculated from absolute values. Infarctions caused the baseline 
of positive inotropic effect and relaxation to be reduced by 38% and 23%, respectively. Heart rates (-
3%) were unaffected, but systemic arterial pressure reduced by 20%. 
In MI rats, ORM-11372 improved maximally positive inotropic effect by 18 ± 6% and by 31 ± 6% in sham 
rats (Figure 8A). Maximal effects were observed at the highest infusion dose of 417 µg/kg/min, 
corresponding to free plasma concentrations of 6.7 ± 2.5 and 4.9 ± 0.4 nM. At the lowest infusion 
dose of 1.7 µg/kg/min, ORM-11372 improved relaxation levels in the MI group by 24 ± 2% (Figure 8B). 
ORM-11372 maximally reduced the heart rate by 14 ± 4% (SHAM -2 ± 2%; Figure 8C). ORM-11372 had 
no systemic arterial blood pressure effects in the MI or SHAM groups (Figure 8D). 
In vivo haemodynamics in rabbits 
ORM-11372 induced a 35 ± 8% (calculated from absolute values) statistically significant increase in 
cardiac contractility in healthy rabbits, at an infusion rate of 833 µg/kg/min (Figure 9A). At rates of 
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17-833 µg/kg/h, ORM-11372 infusions did not have any effects on cardiac relaxation (Figure 9B), heart 
rate (Figure 9C), or systolic blood pressure (Figure 9D) in healthy rabbits. 
Discussion 
Although the first NCX inhibitor, XIP, was a peptide, it enabled us to study the role of NCX under 
physiological and pathological conditions in cells and isolated tissues (Hobai et al., 1997). However, 
it took 20-30 min for NCX to be inhibited; it also inhibited SERCA and PMCA (Enyedi et al., 1993). The 
next important step was the isolation and characterization of the naturally occurring NCX inhibitor 
(NCXIF) (Hiller et al., 2000). It was the first specific, cell membrane-penetrating NCX inhibitor (Shpak 
et al., 2003), but the structure of NCXIF was not published. 
The first generation compounds (Table S1) that were specifically targeted to inhibit NCX were used 
as pharmacological tool to assess the inotropic mechanisms of various drugs like cardiac glycosides 
(Ruch et al., 2003; Tanaka et al., 2007) and insulin (Hsu et al., 2006). The potency of the first 
generation NCX inhibitors was modest and selectivity between NCX and other membrane currents 
was poor, especially towards the L-type Ca2+ current (Birinyi et al., 2005). SEA0400 was positively 
inotropic in rats, but not in rabbits (Farkas et al., 2008), in which the role of NCX is similar to that 
of humans. For the second generation NCX inhibitor ORM-10103 (Koskelainen et al., 2003), the 
selectivity between NCX and other currents were improved (Kormos et al., 2014). The following 
molecule ORM-10962 (Otsomaa et al., 2004) exhibits even better potency and more improved 
solubility (Kohajda et al., 2016). Discovery of ORM-11372 created the ground for the third generation 
NCX inhibitors with the unique structure combined with improved drug likeness. 
ORM-11372 inhibited NCX 1.1 reverse and forward mode currents with a similar potency in both human 
iPS and rat cardiomyocytes. Furthermore, the inhibition of human and rat NCX 1.1 currents were 
shown to be of the same magnitude (IC50 were 5 vs 10 nM). NCX 1.1 expression has been demonstrated 
in iPS-CMs (Fine et al., 2013; Kodama et al., 2019). To our knowledge, the presence or absence of 
the other NCX subtypes in hiPS has not yet been reported. Furthermore, NCX 1.1 expression is tissue 
specific (Lee et al., 1994); it can be stated that ORM-11372 is a potent and selective NCX 1.1 inhibitor 
compared to other cardiac ion channels, but NCX subtype selectivity is unknown. NCX have 
specialized role in excitation-contraction coupling. Cell specific regulation of NCX1 expression is due 
to cardiac specific promoter which leads to very high expression of NCX1.1 in cardiac tissue (Nicholas 
et al., 1998). Hence, the effect of ORM-11372 is cardiac specific. In earlier studies, it was speculated 
that positive inotropic effects could be attributable to the asymmetrical blocking of NCX (Oravecz et 
al., 2018). ORM-11372 induced positive inotropy in healthy and myocardial infarcted rats, although 
it symmetrically inhibited both inward and reverse NCX currents. In rat plasma, the effective free 
concentration range of ORM-11372 was from 4 to 300 nM (Fig S20), corresponding to the NCX inhibition 
range of IC25 to IC80 in rat cardiomyocytes (Fig 4C). ORM-11372 induced positive inotropy even in vivo, 
in the healthy rabbits, in contrast to SEA0400 (Farkas et al., 2008). The fact that the ORM-11372 NCX 
inhibitor is over 10 times more potent than SEA0400 explains its positive inotropic effect in rabbits. 
This was also confirmed in hNCX1-HEK assay (Fig 5). ORM-11372 increased twitch tension (Figure 6D) 
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which indicates increased SR load. Furthermore, unlike SEA0400, ORM-11372 inhibited NCX 1.1 
current selectively, and other cardiomyocyte currents were negligibly inhibited.  
ORM-11372 had no effect on relaxation levels in normal rats and rabbits, but at the lowest dose, it 
improved relaxation levels in myocardial infarcted rats. Rat hemodynamics is subject to limitation of 
the fact that rat cardiomyocyte relaxation depends less on NCX and more on the other Ca2+ handling 
mechanisms. An earlier study conducted in vitro using SEA0400 showed that NCX inhibition caused a 
deterioration in transient Ca2+ levels, but not mechanical relaxation (Szentandrassy et al., 2008). An 
ex vivo study using an isolated perfused rat heart with artificial ionic modification demonstrated that 
NCX inhibition also deteriorated mechanical relaxation levels (Chen et al., 2012). Yet, it must be 
emphasized that the earlier studies were performed using the weaker and less selective inhibitor 
SEA0400 (Table 1), under artificial conditions. ORM-11372 did not affected relaxation in guinea-pig 
papillary muscle (Figure 6G) neither in vivo rabbits due to the activation of compensative Ca2+ 
handling mechanisms in cardiomyocytes, as increased intracellular Ca2+ levels enhance SERCA and / 
or PMCA activity. Furthermore, ORM-11372 had no effects on rest tension (Figure 6E) indicating no 
increase in diastolic calcium. ORM-11372 did not either affect time to peak (Figure 6F) which 
demonstrate that calcium release from ryanodine receptors is normal. Our findings are in line with 
the study using NCXIF. Hemodynamic models of present study were exclusively done on male rats and 
rabbits which might introduce potential bias due to sex differences. Our results with human 
Trabeculae and guinea-pig papillary muscle did not show any differences between sexes although 
number of experiments are low. However, differences in calcium handling activity and NCX 
expression level in cardiomyocytes has been published between sexes, age and regional expression 
of NCX (Janczewski et al., 2010). Therefore, the role of NCX in calcium handling between sexes 
should be systematically furher explored. 
ORM-11372 selectively inhibited INCX over a Kv11.1 current, and provided a safety margin (ratio ≥ 2000) 
of well beyond 30-fold, which was considered adequate for ensuring an acceptable degree of safety 
from arrhythmogenesis (Redfern et al., 2003). Results were also confirmed in human ventricular 
tissue. Furthermore, ORM-11372 can be classified as being non-pro-arrhythmic in humans. 
Although the NCX current seems to be crucial for beat generation (Groenke et al., 2013), even a small 
NCX current is enough to maintain the heart beat (Gao et al., 2013). In the present study, ORM-11372 
had no effects on heart rate in vivo in rats or rabbits. Up to 80% NCX can be inhibited without any 
effects on the heart rate (Figure S20). In vascular arterial cells, NCX contributes to the maintenance 
of the myogenic tone (Zhang et al., 2010). In a manner similar to SEA0400 (Yatabe et al., 2015), ORM-
11372 had no effects on systolic blood pressure. The aforementioned pharmacological properties 
resulted in unique positive inotropic effects without without the risk of hypotension, increase in heart 
rate, or impairment of left ventricular relaxation. 
During the discovery of ORM-11372, multible iterative DMTA-cycles (Design, Make, Test, Analyse) of 
optimization (Andersson et al., 2009) were performed in coherence with the 3R principles, using the 
protein and cell based in vitro methods, before section of the compound for in vivo studies. Group 
size was optimized, but was big enough for obtaining reliable results. Animals were also allowed to 
become habituated to the procedures and the necessary analgesia was used. Rats and rabbits were 
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selected to ensure similar responses and improved prediction capabilities from in vitro to in vivo 
studies, which ultimately would be translated into better efficacy and safety in human studies. To 
improve pharmacokinetic and pharmacodynamic interpretation, the plasma levels of ORM-11372 were 
monitored at the end of each pharmacodynamic experiment. 
The ORM-11372 scaffold was shown to have critical bridged aniline structure with hydrogen donor 
property between the A and the B ring systems (Figure 1 and 2). The 1st and the 2nd generation NCX 
inhibitors lack the hydrogen bond donor in their scaffold. Furthermore, the activity of the ORM-11372 
series exhibited better potency in the screening assay than the known NCX inhibitors (Table S1 and 
S2). This indicates that an additional specific binding interaction was identified between the ligand 
and NCX protein. However, the finding remains speculative due to the lack of other experimental 
evidence e.g. protein-ligand crystal structure. The crystal structure of the mammalian NCX and its 
splice variants are still unavailable, though the crystal structure of the NCX protein of archaebacterial 
Methanococcus jannaschii was published in 2012 (Liao et al., 2012). There are known structural 
differences between the prokaryotic and eukaryotic NCX proteins that might lead to differences in 
the potential binding pockets and selectivity (John et al., 2013; Khananshvili, 2014). Thus, evidence 
regarding the binding pocket for ORM-11372, as well as for the other NCX inhibitors is yet to be 
uncovered. 
Conclusions 
Thus, it can be concluded that ORM-11372 is the first in a class of the third generation of NCX 1.1 
inhibitors with a unique scaffold and improved profile. ORM-11372 is the most potent and selective 
reported NCX 1.1 inhibitor. ORM-11372 selectively inhibits cardiac NCX 1.1 current and induces 
positive inotropic effects in healthy and myocardial infarcted rats, as well as in rabbits. ORM-11372 
has a better hemodynamic profile and similar positive inotropic effects, as compared to dobutamine, 
but did not cause an increase in heart rate or decrease in systolic blood pressure. Intrestingly, at a 
low dose, ORM-11372 improved relaxation in the myocardial infarction model. Studies involving 
human tissues support the classification of ORM-11372 as a non-pro-arrhythmic inhibitor. 
Thus, ORM-11372 can be used as a research tool by researchers, to further study the role and function 
of NCX1.1 in vitro and in vivo. 
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Table 1. NCX inhibition values (n=3) and the selectivity profile towards hERG (n=4) and L-type 
Ca2+ channels (n=4) for selected example compounds. The abbreviation n refers to the number of 
independent plates. 
  
Code  NCX 
IC50 
nM  
hERG   
IC50 µM  
L-type 
Ca2+    
IC50 µM  
Solubility 
class  
ORM-120407   231  2.1  3.1  insoluble  
ORM-11023   156  -  -  -  
ORM-11024   875  -  -  -  
ORM-11165   4  9  2  insoluble  
ORM-11217   210  14.6  -  moderate  
ORM-11190   204  -  -  -  
ORM-11298   31  >10  -  moderate  
ORM-11372   6  10.6  6.1  moderate  
ORM-11817   3  2.4  10.4  insoluble  
ORM-11863   2.5  -  -  insoluble  
ORM-11875   90  -  -  moderate  
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Figure 2. Illustrative chemical structures (out of 135 synthesized molecules) during the chemical 
optimization of the scaffold. ORM-11372 had the most favourable profile overall, out of the 
synthesized derivatives. 
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